Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, will host its 2025 Investor Day on Tuesday, September 9, 2025 from 9:00 a.m. to 12:00 p.m. EDT.
The event will feature presentations by executive management, followed by a Q&A session. In-person attendees will have access to an innovation demonstration and group lunch with management. While in-person attendance is invitation-only, the general public can access the event via webcast by registering online.
Presentation materials will be available on investors.aptar.com on the day of the event.
AptarGroup (NYSE:ATR), a leader in drug and consumer product technologies, reported strong Q2 2025 results with reported sales up 6% to $966 million and core sales growth of 3%. The company's net income increased 24% to $112 million, with earnings per share rising 25% to $1.67.
All three segments - Pharma, Beauty, and Closures - showed positive growth and margin expansion. Pharma segment saw 7% reported sales growth driven by strong demand in prescription medicines and injectables. Beauty segment reported 4% growth, while Closures segment achieved 8% growth led by food and beverage markets.
The company returned $100 million to shareholders through dividends and share repurchases in Q2. For Q3 2025, Aptar expects adjusted EPS of $1.53 to $1.61, anticipating continued strength in Pharma but normalization in naloxone sales.
Aptar Pharma (NYSE:ATR) has announced a significant sustainability milestone with its Freepod® nasal spray pump, used in Haleon's Otrivin® brand, now being manufactured with 52% bio-based feedstock. This marks the first Aptar delivery system using such materials to be commercialized globally.
The innovative solution features an ISCC Plus certified manufacturing process, with the bottle produced using a mass balance approach equivalent to 100% bio-based content. Combined, the pump and bottle components achieve 60% circular material content for the complete nasal spray device. The manufacturing site in Mezzovico, Switzerland, maintains ISCC PLUS certification, ensuring complete material traceability.
This development supports Haleon's sustainability goals of reducing virgin petroleum-based plastic use by 10% by 2025 and by a third by 2030, compared to 2022 levels.
AptarGroup (NYSE:ATR) announced that its nasal drug delivery system was successfully used in a groundbreaking Wake Forest University School of Medicine brain imaging study. The research validated that intranasal insulin effectively reaches 11 key brain regions associated with memory and cognition in older adults, particularly relevant for Alzheimer's treatment.
The study involved 16 older adults (average age 72), including seven cognitively normal individuals and nine with mild cognitive impairment (MCI). Key findings revealed that cognitively normal participants showed higher uptake compared to those with MCI, and women's insulin uptake correlated with cardiovascular health factors. The procedure was well-tolerated, with only two participants reporting mild, temporary headaches.
Aptar Pharma (NYSE:ATR) has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. The strategic acquisition includes an FDA-inspected facility in Boonton, New Jersey, equipped with cGMP cleanrooms, high-potency API suites, and biologics capabilities.
The acquisition strengthens Aptar's early-stage drug development support, particularly for Phase 1 and 2 clinical trials, focusing on orally inhaled nasal drug products (OINDPs). The facility's capabilities align with Aptar's drug delivery solutions portfolio and will help address growing market demand for agile, high-quality cGMP clinical trial material supply services.
AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has declared a quarterly cash dividend of $0.45 per share. The dividend will be paid on August 14, 2025 to stockholders of record as of July 24, 2025.
Additionally, the company announced it will hold a conference call on August 1, 2025 at 8:00 a.m. Central Time to discuss Q2 2025 results. The call will be available via webcast on Aptar's Investors page.
AptarGroup (NYSE:ATR) has unveiled a groundbreaking dual-active material science technology that simultaneously controls moisture and oxygen for pharmaceutical products. This innovative solution extends their 3-Phase Activ-Polymer™ technology to protect sensitive oral solid dose drugs, medical devices, and delivery systems.
The technology represents a significant advancement in pharmaceutical protection, particularly beneficial for GLP-1 medications and various medical devices. It can be customized for different product formats and development stages while helping companies meet ICH stability requirements. Aptar also offers complementary elastomeric components for GLP-1 drug products and integrated digital patient services.
AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing and dispensing technologies, has been recognized as one of TIME's World's Most Sustainable Companies 2025, ranking 244 out of 500 global companies. This marks their second consecutive year on the list.
The company has demonstrated significant sustainability achievements, including maintaining a Platinum level rating from EcoVadis for five consecutive years, placing them in the top 1% of rated companies. Notable metrics include 97.5% renewable global electricity usage and 86% of operational waste avoiding landfill. Aptar has also secured renewable supply agreements in Europe and North America while partnering with organizations like the Ellen MacArthur Foundation to advance sustainability initiatives.